Synthetic Chemistry’s Potential in Deciphering Antimicrobial Peptides
The saga of antimicrobial peptides unfolds as a testament to scientific ingenuity and therapeutic resilience.
The saga of antimicrobial peptides unfolds as a testament to scientific ingenuity and therapeutic resilience.
Scientists are striving to understand bioavailability complexities to ensure the equivalence of drug formulations from different manufacturers, crucial for clinical effectiveness.
In the third part of the Biopharm and PK PharmaFEATURES Primer, we take a deeper dive in mathematical modeling to better estimate drug dosing and generate better predictions of drug efficacy vs time of medications.
Bioavailability, fundamental in pharmacology, explores intricate drug absorption and distribution in the body.
Plasma drug concentrations monitoring allows medication dose adjustment for individualized and optimized drug therapies.
A drug’s physicochemical properties play a crucial role in their effectiveness and safety.
QSAR promises to improve serotonin studies.
Understanding drug toxicity mechanisms is vital for patient safety and treatment efficacy.
The path from target identification to hit discovery showcases the scientific community’s ingenuity and perseverance.
This FBDD article discusses its fundamental principles, workflow, library selection criteria, expansion strategies, and optimization approaches.
Let’s explore how advanced technologies are actively transforming biomedical discovery, particularly in cancer research.
As costs soar and drug approvals dwindle, research-based companies face a formidable challenge—addressing poorly soluble drug candidates.
Targeted protein degradation proximity agents are emerging modalities in biology and drug discovery.
AI’s revolutionary influence on pharmaceutical innovation is evident as it continues to permeate the industry.
Dr. Satz played a pivotal role in positioning actinium-225 as a promising radionuclide for targeted alpha therapy.
Driven by the dynamic duo of Dr. Stan and Ms. Rose Satz, AIP brings over four decades of nuclear pharmacy and radiochemistry expertise.
AIP ventures into uncharted territory of rare pediatric diseases.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings